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Summary Oral methotrexate (MTX) is a highly effective drug for the treatment of severe psoriasis. A limitation
of this treatment is its potential hepatotoxicity. In the present prospective study the value of dynamic 
hepatic scintigraphy (DHS) and serum aminoterminal propeptide of type III procollagen (PIIINP) 
were investigated as screening methods for early detection of MTX-induced hepatic damage. These 
relatively non-invasive procedures were compared with the liver biopsy classification, until now the 
gold standard to assess MTX-induced liver damage. Twenty-five MTX patients were studied. The 
mean cumulative MTX dose was 3-9 g (range 0 -2-11*1  g). Twenty-one patients had a normal liver 
histology (grade I), three patients had steatosis (grade II), and one patient mild fibrosis (grade IIIA), 
Seven additional patients with non-MTX related hepatic cirrhosis were included as disease controls.
DHS showed a clear-cut separation between the portal contribution of the MTX patients with 
grade I liver histology, and that of all other patients. A portal contribution larger than 52% was 
associated w ith a >95%  chance of normal liver histology. If this cut-off value had been used to 
postpone the liver biopsy, this would have resulted in at least a 55% reduction in the number of 
biopsies in patients with a normal liver histology. DHS appeared to be very promising as a screening 
test to differentiate between the presence or absence of MTX-induced hepatic damage, but appeared 
not suitable to grade the severity of hepatic damage. Although a global relationship was demon­
strated between serum PIIINP concentration and hepatic damage, single measurements in indivi­
dual patients were not reliable. The combination of PIIINP measurements with DHS had only a 
limited additional value above DHS alone. The present study indicates that DHS has great promise for 
the detection of early MTX-induced hepatic damage. Pending further studies, regular liver biopsies 
remain mandatory for the safe prolonged use of MTX in psoriasis patients.
Oral methotrexate (MTX) is a highly effective drug for
1
the treatment of severe psoriasis, MTX treatment, 
however, is associated with potential hepatotoxicity. 
Conventional serum liver function tests Eire not reliable 
as indicators of hepatic damage. According to inter­
national guidelines, a liver biopsy has to be performed in 
the initial phase of treatment and subsequently ; 
each cumulative dose of 1-5 g.2,3, At present, histolo­
gical evaluation of liver biopsies is the gold standard to
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I
according to the methodology of Ferguson et al. In 
short, the uptake of " mTc sulphur colloid in the spleen 
is proportional to the arterial uptake by the liver. By 
subtracting this arterial contribution from the total liver 
uptake, the portal contribution to the total liver blood 
flow can be computed. The low-pressure portal vein 
system is more sensitive for changes in the structure of 
the liver parenchym than the high-pressure arterial 
system, and the portal contribution decreases in cases 
of fibrosis or cirrhosis.
Another interesting screening test is the measure­
ment of the serum level of aminoterminal propeptide of 
type III procollagen (PIIINP).15“ 18 Hepatic fibrosis is 
characterized by increased synthesis and the deposition 
of collagen, predominantly type III. Collagen molecules 
are derived from procollagen by cleaving the terminal 
peptides, which are subsequently released into the 
circulation.19 Measurement of PIIINP, with a radio­
im m unoassay,20 may be suitable to detect and monitor 
liver damage.21 This test is not organ-specific, as 
increased PIIINP levels have also been demonstrated 
in systemic sclerosis, localized scleroderma, and rheu­
matoid arthritis.22,23
In the present study the value of both DHS and serum  
PIIINP, alone and in combination, for the detection of 
MTX-induced hepatic damage was prospectively inves­
tigated. The liver biopsy results were used as a gold 
standard. A small group of patients with non-MTX- 
related hepatic cirrhosis was included as 
controls.
v,ase
Patients and methods
Patients
In the period September 1.993 to October 1994, all MTX 
patients who were scheduled15 to undergo a liver biopsy 
were asked to participate in the study. All patients were 
treated according to the Weinstein schedule (maximum  
weekly dose 15 m g/day).4 All investigations in indivi­
dual patients were completed within a period of 10 
weeks. DHS was performed ^  2 weeks after the liver 
biopsy. Details on age and gender of the patients, 
indication for MTX treatment, duration of treatment, 
cumulative dose, and the presence or absence of arthri­
tis, were obtained from the medical records. Several 
patients from the Department of Gastroenterology, with 
non-MTX-related liver cirrhosis, were included as dis­
ease controls. The study was approved by the hospital’s 
Medical Ethical Committee and all patients gave written 
informed consent.
Liver biopsies in methotrexate patients
Liver biopsies were performed, according to the 
Menghini technique, at the Department of Gastro­
enterology. The biopsies were prepared and classified, 
according to the guidelines of Roenigk et a l , 5 by one 
pathologist: liver biopsy classification (LBC) grade 1, no 
abnormalities or mild steatosis, nuclear variability or 
portal inflammation; LBC grade II, moderate or
nuclear variability portal inilam-
IIIA, mild fibrosis;
severe
mation or necrosis; LBC
LBC grade i moderate to severe LBC
grade IV, cirrhosis.
Dynamic hepatic scintigraphy
After overnight fasting, the patient was positioned 
supine on the couch of the dual-headed gamma 
camera, connected to an ICON computer (MultiSPECT 
II, Siemens, Hofmann Estates, IL, U.S.A.). The gamma 
camera was equipped with ‘Low Energy High Resolu­
tion’ collimators. The liver and spleen were positioned 
in the centre of detectors measuring 53 x 39 cm. Imme­
diately after a rapid injection of 111 MBq " mTc sulphur 
colloid, with a particle size of about 30 nm, dynamic 
planar gamma camera images were recorded for 160  
frames of 0-5 s each, in a 64  x  64 matrix. Analysis was
performed according to the m ethods,13,14
Regions of interest were drawn around the liver, on 
an anterior sum-image, and around the spleen, on a
sum-image. Time activity curves for both
organs were 
liver to spleen 
was also
r
Cmd smoothed. The ratio of
, On the basis of this curve the onset 
of portal input was estimated as the m om ent when the
ratio curve s t o j e , by a plateau. The 
curve started to rise was 
used to normalize the liver to the spleen curve over the 
complete duration of the study. The spleen curve was 
subtracted from the normalized liver curve, resulting in 
the portal curve. The portal contribution at 25, 30, 35
40  s post-injection, was a as
between the activity in the portal curve and the normal-
2 of therCized liver curve, 
total liver curve. All 
three observers (the first
as a
were am
* t
blinded by 
The results of
W.C.A.M.B., physicist at the Department of Nuclear
, were
varie
analysis. The inter-
was evaluated. The
dose was 1 * 1 m Sv/scan (the background radiation on
is
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Serum aminoterminai propeptide of type III procollagen
Sera were collected and stored at — 20°C until analysis. 
PIIINP concentrations were measured with a radio­
immunoassay based upon the hum an propeptide 
(FARMOS Diagnostica, Espoo, Finland).20 The reference 
range for adults (based on healthy Finnish blood donors), 
as provided by the manufacturer, is 1- 7 -4 -2  /xg/L
most, 5% of the patients with such a high portal 
contribution have a higher LBC than grade I. The 
inter-observer variability of the DHS was evaluated by 
recomputing the posterior probabilities for a grade I 
LBC, using the values of the portal contribution as they 
were measured by the two other observers (R.J.v.D.G. 
and A.L.A.K.).
Patient questionnaire
After completion of the liver biopsy and DHS, a ques­
tionnaire was sent to all MTX patients. A subjective 
judgement of mild, medium, or strong discomfort scored 
1 -3  points, and a judgement of absent, minimum, 
medium, or strong fear scored 0 - 3  points. The patients 
were asked which procedure they preferred.
Statistical methods
In order to distinguish patients w ith a LBC grade I from 
the other patients, linear discriminant analysis was 
used.24 With this method, posterior probabilities for a 
grade I LBC can be computed, given the values of one or 
more discriminating variables and given the prior prob­
ability (i.e. the probability w ithout any further knowl­
edge). As possible discriminating variables, the portal 
contribution (DHS), and the PIIINP were used. A m ini­
mal prior probability of 66%, for a grade I LBC, was 
used; this percentage originates from an earlier study. 
When the corresponding posterior probability, given 
the cut-off value of a discriminating variable (e.g. the 
portal contribution) exceeds 95%, this m eans that, at
Results
Patients
Twenty-live MTX patients (12 males and 13 females) 
were included in the study. Twenty-four patients had 
severe psoriasis and one had Reiter’s disease. The mean 
age was 52 years (range 3 1 —75 years). The mean 
cum ulative MTX dose was 3*9 g (range 0 -2 -1 1 -1  g), 
and the mean duration of treatment was 90 months 
(range 4 - 2 8 8  months). Six of the 25 patients also had 
psoriatic arthritis. In seven patients, three males and 
four females, with non-MTX-related hepatic cirrhosis, 
DHS and/or PIIINP determinations were performed. 
Their mean age was 53 years (range 4 3 - 7 5  years). In 
four patients, cirrhosis was induced by alcohol abuse 
and in three by autoimmune hepatitis.
Liver biopsies in methotrexate
Twenty-one patients (84%) had LBC grade I, three
(12%) had grade II, and one )) grade IIIA. No
complications occurred during or after liver biopsies.
Figure 1. Portal contribution in relation to 
histological classification of liver biopsies 
(grades I—III). Non-methotrexate related 
cirrhosis patients are included in a separate 
column (grade IV).
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Histological c la ss if ica t ion  of liver biopsies {n = 30)
Figure 2. Serum aminoterminal propeptide 
of type III procollagen (PIIINP) values in 
relation to the histological classification of 
liver biopsies (grades I—L11). Non-
a > re u i ■ ■ i ' ' pt * 9are
included in a separate column (grade IV).
Dynamic hepatic scintigraphy
DHS was performed in 22 of the 25 MTX patients. The 
portal contribution computed at 3 5 s post-injection had 
the highest discriminating power and was used for 
further analysis. The mean portal contribution at 3 5 s 
was 50-4% [standard deviation (SD) 13*1]. In the 18 
patients with LBC grade I, the mean portal contribution 
was 54-8% (SD 9-5), the three patients with LBC grade 
II had portal contributions of 20-4%, 28-9%, and
with grade III LBC had a38-0%, and
portal contribution of 37-0%. Figure 1 shows the 
portal contribution of all patients in relation to their
LBC (grades I-TII). There was a separation
normal liver histology (grade I) and all other patients. 
The values of the patients w ith grade II and III LBC were 
in the same range. The portal contributions of five 
cirrhosis patients are show n in a separate column of 
Figure 1 (grade IV). Their m ean portal contribution 
(31%), was in the same range as that of the MTX 
patients with grade II—III LBC.
between the portal contribution of the patients with a
Serum-aminoterminal propeptide of type III procollagen
The mean PIIINP, in all 25 MTX patients, w as 3*8 /¿g/1 
(SD 1*3). In the patients w ith LBC grade I, the mean 
PIIINP was 3*6 /ig/1 (SD 1-0). The three patients with 
LBC grade II had PIUNP values of 3*2, 3*0, and 7*0 //g/1, 
and the patient with LBC grade III had a PIIINP value of
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Figure 3. Liver biopsy classification 
(O =  grade I, ▲ ~ grade 11 / 111, * cirrhosis 
patients, grade IV), dynamic hepatic 
scintigraphy (DHS) portal contribution at 
3 5s and PIIINP values, for all 52 patients. 
Discriminant function lines (cut-off lines) 
for DHS only (continuous vertical line), and 
for both DHS and PIIINP (Interrupted
line). Dolled line parallel to 
patients with unknown porlal 
contribution. Dotted line parallel to //-axis:
;nls with unknown PIIINP value.
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6 '2 /ig /l. Figure 2 the of all
patients in relation to their LBC (grades 1-111). Although  
the mean PIIINP values in patients w ith grade II—111 
LBC were significantly higher than those with grade I 
LBC, isolated values did not discriminate between indi­
viduals with and without hepatic damage. The six 
patients with psoriatic arthritis all had a LBC grade I, 
and their mean PIIINP was 3 ' 7  //,g/ 1. The PIIINP values 
of five cirrhosis patients are shown in a separate column
(grade IV). Their m ean PIIINP (8*0 /¿g/l) was 
significantly higher than that of the MTX patients, with  
an overlap for the individual results. If the MTX and the
cirr patients are combined, three of \
patients (3 3%) with abnormal histology, had normal 
PIIINP values.
postpone the liver biopsy, in the instance of a portal 
contribution >52% , the number of biopsies in patients 
with a normal liver would have been reduced from 5 5 
to 8 3%, depending on the observer.
ques t
aire was returned by 17 of the 2 5 MTX
patients (68%). The total discomfort score was 28 points 
for the liver biopsy and 20 points for the DHS. The total
ar score was 10 points 
points for 
preferred
r biopsy and six 
out of the 1 7 patients (88%)
Discriminant analysis 
methotrexate patients
The cut-off value of the portal contribution 
corresponding to a >95%  posterior probability to a 
LBC grade I, was 52% (Fig. 3). Of the 18 patients with 
a normal liver histology, 10 (5 5%) had posterior prob­
abilities >95%, while none of the patients with abnor­
mal histology met this criterion (Fig. 3). Subsequently, it 
was investigated whether the addition of PIIINP as 
second discriminating variable could enhance the pos­
terior probabilities. This appeared to be the case as, with 
this, 14 (78%) of the 18 patients with normal liver 
histology had posterior probabilities >95% , compared 
to none of those with abnormal histology (Fig. 3). The 
variable PIIINP, on its own, did not produce a useful 
cut-off point. The cirrhosis
3 to show that their position is clearly left of 
the cut-off limit. In the discriminant analysis, however, 
only the MTX patients have been included.
To evaluate inter-observer varit
n r/>e me m
of the
after performance of discriminant analysis, it was corn-
two other observers would have
percentage 
a >95%) chance of LBC grade I. IL is 
important that none of the observers produced false 
negative results (computed posterior probability >  9 5% 
and abnormal liver histology). The percentage of false- 
positive results (computed posterior probability ^ 9  5(X 
and normal liver histology) differed between the three 
observers (W.C.A.M.B., 45%; A.L.A.K., 22%; and 
R.J.v.D.G., 17%). If the PIIINP is added as a second 
discriminating variable, only the percentage false
)
for W.C.A.M.B. changed,
namely from 45 to 22%. If the decision was made to
Discussion
In the present study a clear-cut separation between the 
portal contribution of MTX patients with a LBC grade I
and all could be demonstrated.
appeared not to be suitable for the determination of 
the severity of hepatic damage. The patients with 
steatosis (grade II) had a m uch lower mean portal 
contribution than the patients with grade 1 LBC (-29*1
*
vs. 54*8%), This suggests that a grade II LBC indeed 
reflects early MTX-induced hepatic damage. McHenry
et a l 13 performed 87 paired DHS and liver biopsies in 6 3
psoriatic MTX patients, and reported a 
value of normal DHS for fibrosis grade 0 -1 5% i),
and a low pi: value of an -mal DHS for
*fibrosis of grade 2 or worse (25%). McLaren et al. 
reported a significant reduction in the portal contribu-
u s  p iin 41 non-MTX-rel 
pared to 3 3 healthy c
By means of
, in our s
analysis, it has 
, that a portal c
aof >52% , in a MTX patient, was assock 
>95%  chance of a LBC grade I. If this cut-off value of 
52% had been used to postpone the liver biopsy, this 
would have reduced the number of biopsies, by at least 
55%, in the patients with a normal liver histology. None 
of the three observers produced any false negative 
results.
Zachariae et report on PIIINP levels in 170
patients with psoriasis. Patients
\
s or
significantly elevated mean 1 
claimed that 
MTX
psoriatic arthritis, had
luthors
; n u r
n i i t i be in
normal PIIINP levels. Like
Gors we cannot confirm these conclusions,
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as a considerable number (i.e. six to eight of 24, 2 5 -  
33%) of patients without arthritis and with fibrosis, had 
normal values of PIIINP. Furthermore, four of 18 (22%) 
of patients with both arthritis and liver fibrosis had 
normal PIIINP values. Risteli et a l  reported elevated 
PIIINP level in eight of nine patients with fibrosis or 
cirrhosis, and concluded that the number of biopsies 
could be significantly reduced in patients with normal 
PIIINP values, despite the fact that six of 15 patients 
(40%) with PIIINP values in the normal range had
or Mitchell et til 17 on a
controlled study with 51 MTX-treated psoriatics, and 
concluded that isolated PIIINP measurements cannot 
discriminate between individuals with and without 
significant liver pathology. The conclusion from the 
present study is in accordance with that of Mitchell 
et a l :17 there was a global relation between PIIINP 
values and hepatic damage, but one-off readings 
appeared to be unreliable for the screening of individual 
patients. Patients with psoriatic arthritis had PIIINP 
levels in the same range as the other patients. Probably, 
there is scope for the use of PIIINP values for the regular 
monitoring of individual patients. The additional value 
of PIIINP measurements to DHS in individual patients, 
was very limited in the present study, and could be 
demonstrated only in one of the three observers 
(W.C.A.M.B.). The subjective judgement of both proce­
dures by the MTX patients was clearly in favour of DHS.
The present study indicates that DHS, a relatively 
non-invasive procedure, is very promising for the detec-
MTX-induced hepatic damage. Thistion of
approach may lead to a considerable reduction of the 
number of liver biopsies, in the near
rming liver biopsies according to
s, remains the gold standard 
use of MTX in the treatment
the international g 
for the safe and 
of psoriasis.
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